Innovation in antibiotics is ailing. 'Brain drain' may kill it

Asantibioticsresearchshrivels,thebraindrainawayfromthisfieldwillhavemanylabslookingthisempty.AdobeIn Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular




comprehensive

author：Wikipedia    Page View：48731
John Crowley pictured with his daughter Megan Crowley — health policy news from STAT
John Crowley pictured with his daughter Megan. Crowley family

WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John Crowley as its new CEO, the organization announced Tuesday.

Crowley came to biotech when his children were diagnosed with a rare genetic neuromuscular disease. He started working at Bristol Myers Squibb, and started Novazyme, which was eventually successful in creating an enzyme replacement therapy for Pompe disease. He later started and worked for several different biotech companies, most recently with Amicus Therapeutics, which had a drug approved to treat the disease in September.

advertisement

The trade association’s board chair, Ted Love, served on the board of the company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： ASCO Daily Recap: Safety data from Novartis, survival from Pfizer
Next article： Affirmative action in medical school literally saved lives